Study number 779857
Dates
Apr 23 2026-Jul 03 2026
Location
Dallas, Texas
Age
18-65
Gender
Male and Female
Smoker
Yes
Compensation
$12,049
Group
C3
This is a research study for a drug approved by the U.S Food and Drug Administration (FDA) for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. This study drug is also being developed for the potential treatment of autoimmune diseases, conditions in which the immune system mistakenly attacks the body.
Dallas, TX is currently recruiting Healthy Adults, ages 18-65.
Refer a friend & receive $350 per qualified referral
Women Eligibility Criteria
Smoking Criteria
Body Mass Index
Screening procedures
Check-in: April 23
Check-out: April 24
Follow-up visits: April 26, 28, May 1, 4, 8, 15, 22, 29, Jun 5, 12, 19, 26, Jul 3
Phone calls: May 29, Jun 12, 26